Healthcare
Regencell Bioscience Holdings Limited(RGC)
Live Price
Offline$12.01
-18.96% today
Window Change
-49.75%
Window
May 29, 2026 → Jun 18, 2026
- Market Cap
- $14.40B
- Revenue Growth
- 0.0%
- EPS Growth
- +17.2%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Regencell Bioscience Holdings Limited (RGC) is a Healthcare stock with a market cap of $14.40B and listed on NASDAQ. The stock last traded around $12.01 and down 49.7% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.2%, free cash flow +18.5% with operating margin 0.0% and ROIC -69.8%. Stock Foundry combines RGC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +17.2%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RGC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RGC Max Drawdown
-50.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RGC and SPY.
Company Overview
Regencell Bioscience Holdings Limited
NASDAQ Capital Market
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
- Leadership
- Yat-Gai Au
- IPO Date
- Jul 16, 2021
- Employees
- 12
- Street Address
- First Commercial Building
- Mailing
- Causeway Bay, KY1-1107
- Region
- Causeway Bay, HK
- Reporting Currency
- USD
- Investor Line
- 852 2155 0823
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- 2962.7
Growth
- Revenue
- 0.0%
- EPS
- +17.2%
- Free Cash Flow
- +18.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -61.9%
- ROIC
- -69.8%
Balance Sheet
- Debt/Equity
- 0.11
- Current Ratio
- 7.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.